Jakarta, TheIndonesiaPost – SOE Minister Erick Thohir revealed that the Corona vaccine could only be produced in January or February 2021. This follows that 2,400 doses of COVID-19 vaccine from China were being tested by PT Bio Farma.
“What you need to know is that the vaccine will be produced but it will only be January-February next year, which means there are still 6-7 months we have to face this covid, which is not only in Indonesia, but all countries in the world,” Erick said while inaugurating the Ferizy application via video conference, (7/25/2020).
Erick appealed to the entire community to continue to implement health protocols in a disciplined manner, starting using masks, washing hands, to keeping physical distance and while waiting for the vaccine to be produced.
“There is still around six to seven months for the community to participate in breaking the chain of the spread of COVID-19 by implementing health protocols until vaccines are actually produced,” Erick Thohir said.
“There is no longer a term that should be threatened with wearing a mask, fined a new use, but this protocol uses a mask, washing hands, keeping a distance, must be our top priority if we want to feel safe again,” he said.
Before the third phase of clinical trials the COVID-19 vaccine will be carried out in August 2020. Bio Farma itself has received 2,400 vaccines from Sinovac, China.
“This can succeed if the people are united, of course I hope to be supported by all those present, and insha Allah we are all the central government, regional government, the united community facing COVID-19,” he said.
Director of Bio Farma Honesti Basyir said, the clinical trial of the COVID-19 vaccine was scheduled to run for six months so it was targeted to be completed by January 2021. If it goes well, then Bio Farma will produce it in the first quarter of 2020.
“If the clinical trial of COVID-19 vaccine stage 3 runs smoothly, Bio Farma will produce it in the upcoming Q1 2021, and we have prepared its production facilities at Bio Farma, with a maximum production capacity of 250 million doses,” Honesti said.
Honesti said, the reason for choosing Sinovac as a partner is the vaccine platform / vaccine manufacturing method used by Sinovac, which is the same as the competency held by Bio Farma today. With the inactivation method, Bio Farma already has experience in making vaccines such as the Pertussis vaccine. (ojn / bbs)
Comment